##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Mar 25, 2019

Morsen Landonishi  

Abstract

The genitourinary Chlamydia trachomatis infection is a crucial part of sexually transmitted disease worldwide. In recent years, the incidence rate has increased dramatically, and the proportion of asymptomatic infections is particularly large. Therefore the burden for preventing and controlling its epidemic is severe. With the development of laboratory technology and genomics, the understanding on the molecular epidemiology of genital Chlamydia trachomatis is gradually clearer than ever, and the monitor on its epidemic trends and strain variation is becoming more effective.

##plugins.themes.bootstrap3.article.details##

Keywords

Chlamydia Trachomatis, Genitourinary Infection, Epidemiology, Molecular Classification

References
1. Woodhall SC, Gorwitz RJ, Migchelsen SJ, Gottlieb SL, Horner PJ, Geisler WM, Winstanley C, Hufnagel K, Waterboer T, Martin DL, Huston WM, Gaydos CA, Deal C, Unemo M, Dunbar JK, Bernstein K. Advancing the public health applications of Chlamydia trachomatis serology. Lancet Infect Dis 2018; 18:e399-e407.

2. Smelov V, Thomas P, Ouburg S, Morré SA. Prevalence of genital Chlamydia trachomatis infections in Russia: systematic literature review and multicenter study. Pathog Dis 2017; 75. doi: 10.1093/femspd/ftx081.

3. Schust DJ, Ibana JA, Buckner LR, Ficarra M, Sugimoto J, Amedee AM, Quayle AJ. Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection. Curr HIV Res 2012; 10:218-227.

4. Rawre J, Juyal D, Dhawan B. Molecular typing of Chlamydia trachomatis: An overview. Indian J Med Microbiol 2017; 35:17-26.

5. Pedersen LN, Herrmann B, Møller JK. Typing Chlamydia trachomatis: from egg yolk to nanotechnology. FEMS Immunol Med Microbiol 2009; 55:120-130.

6. Pedersen LN, Pødenphant L, Møller JK. Highly discriminative genotyping of Chlamydia trachomatis using omp1 and a set of variable number tandem repeats. Clin Microbiol Infect. 2008; 14:644-652.

7. Peuchant O, Le Roy C, Herrmann B, Clerc M, Bébéar C, de Barbeyrac B. MLVA subtyping of genovar E Chlamydia trachomatis individualizes the Swedish variant and anorectal isolates from men who have sex with men. PLoS One 2012; 7:e31538.

8. Morré SA, Ossewaarde JM, Savelkoul PH, Stoof J, Meijer CJ, van den Brule AJ. Analysis of genetic heterogeneity in Chlamydia trachomatis clinical isolates of serovars D, E, and F by amplified fragment length polymorphism. J Clin Microbiol 2000; 38:3463-3466.

9. Shima K, Wanker M, Skilton RJ, Cutcliffe LT, Schnee C, Kohl TA, Niemann S, Geijo J, Klinger M, Timms P, Rattei T, Sachse K, Clarke IN, Rupp J. The genetic transformation of chlamydia pneumoniae. mSphere 2018; 3. pii: e00412-18.

10. van Ess EF, Eck-Hauer A, Land JA, Morré SA, Ouburg S. Combining individual Chlamydia trachomatis IgG antibodies MOMP, TARP, CPAF, OMP2, and HSP60 for tubal factor infertility prediction. Am J Reprod Immunol 2019: e13091.

11. Sullivan B, Glaab J, Gupta RT, Wood R, Leiman DA. Lymphogranuloma venereum (LGV) proctocolitis mimicking rectal lymphoma. Radiol Case Rep 2018; 13:1119-1122.

12. Mihailovic J, Inic-Kanada A, Smiljanic K, Stein E, Barisani-Asenbauer T, Cirkovic Velickovic T. Lysine acetylation of major Chlamydia trachomatis antigens. EuPA Open Proteom 2016; 10:63-69.

13. Gao XB, Xiao M, Wang J, Liu YJ, Liu QZ, Qi ML. Optimization of candidate proteins for serological screening of Chlamydia trachomatis infection. Genet Mol Res 2015; 14:12240-12246.

14. Huntington SE, Burns RM, Harding-Esch E, Harvey MJ, Hill-Tout R, Fuller SS, Adams EJ, Sadiq ST. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. BMJ Open 2018; 8:e020394.

15. Venter JME, Mahlangu PM, Müller EE, Lewis DA, Rebe K, Struthers H, McIntyre J, Kularatne RS. Comparison of an in-house real-time duplex PCR assay with commercial HOLOGIC® APTIMA assays for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis in urine and extra-genital specimens. BMC Infect Dis 2019; 19:6.

16. Soler M, Belushkin A, Cavallini A, Kebbi-Beghdadi C, Greub G, Altug H. Multiplexed nanoplasmonic biosensor for one-step simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine. Biosens Bioelectron 2017; 94:560-567.

17. Hocking JS, Temple-Smith M, Guy R, Donovan B, Braat S, Law M, Gunn J, Regan D, Vaisey A, Bulfone L, Kaldor J, Fairley CK, Low N; ACCEPt Consortium. Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet 2018; 392:1413-1422
How to Cite
Landonishi, M. (2019). Molecular Epidemiology of Chlamydia Trachomatis Infection in the Genitourinary Tract. Science Insights, 28(2), 25-28. https://doi.org/10.15354/si.19.re077
Section
Review